NCT04942080View on ClinicalTrials.gov

Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)

NARecruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

April 28, 2023

Study Completion Date

April 28, 2026

Conditions
Myeloproliferative NeoplasmEssential ThrombocythemiaPrimary Myelofibrosis, Prefibrotic StagePrimary Myelofibrosis, Fibrotic Stage
Interventions
BIOLOGICAL

CALR allele burden quantification

"* DNA extraction from blood sample for CALR mutation quantification (fragment analysis)~* at diagnosis and follow-up (inclusion period: 3 years)~* max 1 sample/year~* secondary outcome: mutational landscape by Next Generation Sequencing (NGS) analysis at diagnosis"

Trial Locations (1)

Unknown

RECRUITING

CHU Angers, Angers

All Listed Sponsors
collaborator

Ligue contre le cancer, France

OTHER

lead

University Hospital, Angers

OTHER_GOV